Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2005-07-26
2005-07-26
Henley, III, Raymond (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
Reexamination Certificate
active
06921772
ABSTRACT:
The level of the leukemic lymphocytes in patients suffering from chronic lymphocytic leukemia (CLL) is reduced by the administration of certain indole or carbazole compounds, such as the nonsteroidal anti-inflammatory drug etodolac or related indole or carbazole compounds.
REFERENCES:
patent: 3053255 (1962-09-01), Meyer
patent: 3710795 (1973-01-01), Higuchi et al.
patent: 3843480 (1974-10-01), Dreher
patent: 3843681 (1974-10-01), Demerson et al.
patent: 3939178 (1976-02-01), Demerson et al.
patent: 3948254 (1976-04-01), Zaffaroni
patent: 3948262 (1976-04-01), Zaffaroni
patent: 3974179 (1976-08-01), Demerson et al.
patent: 3993073 (1976-11-01), Zaffaroni
patent: 4310509 (1982-01-01), Berglund et al.
patent: 4460562 (1984-07-01), Keith et al.
patent: 4466953 (1984-08-01), Keith et al.
patent: 4482534 (1984-11-01), Blank
patent: 4485097 (1984-11-01), Bell
patent: 4505891 (1985-03-01), Ito
patent: 4533540 (1985-08-01), Blank
patent: 4542012 (1985-09-01), Dell
patent: 4542013 (1985-09-01), Keith
patent: 4560555 (1985-12-01), Snider
patent: 4585877 (1986-04-01), Demerson et al.
patent: 4597961 (1986-07-01), Etscorn
patent: 4608249 (1986-08-01), Otsuka et al.
patent: 4686213 (1987-08-01), Ferdinandi et al.
patent: 4748252 (1988-05-01), Ferdinandi et al.
patent: 4806356 (1989-02-01), Shaw
patent: 4940587 (1990-07-01), Jenkins et al.
patent: 5561151 (1996-10-01), Young
patent: 5599946 (1997-02-01), Vincenzo et al.
patent: 5776967 (1998-07-01), Kreft et al.
patent: 5824699 (1998-10-01), Kreft et al.
patent: 5955504 (1999-09-01), Wechter
patent: 5968974 (1999-10-01), Kargman et al.
patent: 6545034 (2003-04-01), Carson et al.
patent: 6573292 (2003-06-01), Nardella
patent: WO 96/28148 (1996-09-01), None
patent: WO 98/09603 (1997-09-01), None
patent: WO 97/48391 (1997-12-01), None
patent: WO 01/06990 (2001-02-01), None
patent: WO 02/12188 (2002-02-01), None
Bellosillo, et al., Aspirin and Salicylate Induce Apoptosis and Activation of Caspases in B-Cell Chronic Lymphocytic Leukemia Cells,Blood, 92(4):1406-1414 (1998).
Duffy, et al., Enhancement of Chemotherapeutic Drug Toxicity to Human Tumour Cells In Vitro by a Subset of Non-steroidal Anti-inflammatory Drugs (NSAIDs),European Journal of Cancer, 34(8):1250-1259 (1998).
Heath, Jr., Nonsteroidal Antiinflammatory Drugs and Human Cancer; CANCER; Nov. 15, 1994; vol. 74, No. 10, pp2885-2888.
McCracken; Antiproliferative Effects of the Enantiomers of Flurbiprofen; J Clin Pharmacol 1996: 36:540-545.
Nardella, F, et al., Enhanced clearance of leukemic lymphocytes in B cell chronic lymphocytic leukemia (CLL) with etodolac, Arthritis & Rheumatism, vol. 42, no. 9 Suppl. 1999, p. S56 XP 008009568.
Piazza, G.A., et al., Apoptosis primarily accounts for the growth-inhibitory properties of sulindac metabolites and involves a mechanism that is independent of cyclooxygenase inhibition, cell cycle arrest, and p53 induction, Cancer Research 57:2453-2459 (1997).
Riley, T.N., et al., New Drugs a Six Month Review, U.S. Pharmacist, vol. 16, no. 9, 1991, pp. 34-60.
Thun, Aspirin NSAIDs, and Digestive Tract Cancers,Cancer and Metastasis Reviews, 13:269-277 (1994).
Wechter,Rac-Flurbiprofen Is More Ulcerogenic Than Its (S)-Enantiomer,Chirality5:492-494 (1993).
Wechter; R-Flurbiprofen Chemoprevention and Treatment of Intestinal Adenomas in the APCMin/+Mouse Model: Implications for Prophylaxis and Treatment of Colon Cancer;Cancer Research; 1997; 57:4316-4324.
Wechter; R-Flurbiprofen (E-7869), a chemopreventive and treatment of cancer; Inflammopharmacology; 2000; vol. 8, No. 2, pp. 189-206.
Delacroix-Muirheid C.
Henley III Raymond
Pillsbury Winthrop Shaw & Pittman LLP
Salmedix, Inc.
LandOfFree
Methods and compositions for the treatment of chronic... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods and compositions for the treatment of chronic..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods and compositions for the treatment of chronic... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3392543